Table 1. Demographic and Clinical Characteristics of CHIIP Study Participants Compared With the Overall CCSS Cohort.
Characteristics | Participants, No. (%) | |
---|---|---|
CHIIP (n = 293) | CCSS (n = 11 337)a | |
Age, median (range) at assessment, y | 39.9 (21.5-65.0) | 36.8 (16.0-65.9) |
Sex | ||
Male | 149 (50.9) | 5419 (47.8) |
Female | 144 (49.2) | 5918 (52.2) |
Race | ||
American Indian or Alaska Native | 0 | 55 (0.5) |
Asian | 5 (1.7) | 160 (1.6) |
Black | 7 (2.4) | 498 (4.6) |
Pacific Islander | 2 (0.7) | 10 (0.1) |
White | 267 (91.1) | 10195 (89.3) |
>1 Race or otherb | 12 (4.1) | 318 (3.1) |
Unknown | 0 | 101 (0.9) |
Ethnicity | ||
Hispanic or Latino | 23 (7.8) | 710 (6.5) |
Not Hispanic or Latino | 270 (92.2) | 10537 (92.7) |
Unknown | 0 | 90 (0.9) |
Age at diagnosis, median (range), y | 9.3 (0.0-20.9) | 7.3 (0.0-21.0) |
Cancer diagnosis | ||
Bone cancer | 36 (12.3) | 951 (7.4) |
Central nervous system tumor | 23 (7.9) | 2000 (15.5) |
Hodgkin lymphoma | 60 (20.5) | 1380 (10.7) |
Kidney tumor | 32 (10.9) | 1070 (8.3) |
Leukemia | 94 (32.1) | 3384 (38.4) |
Non-Hodgkin lymphoma | 23 (7.9) | 936 (7.2) |
Neuroblastoma | 14 (4.8) | 843 (6.5) |
Soft tissue sarcoma | 11 (3.8) | 773 (6.0) |
Cancer treatment exposuresc | ||
Anthracycline chemotherapy | 222 (75.8) | 8689 (83.0) |
Any radiation | 203 (69.3) | 5906 (50.8) |
Self-reported health care insurance | 273 (93.2) | 10 477 (92.6) |
Self-reported routine care visit within past 2 y | 262 (89.4) | 10 324 (91.3) |
Self-reported history of diagnosed cardiovascular conditions | ||
Hypertension | 94 (32.1) | 2019 (16.3) |
Dyslipidemia | 109 (37.2) | 2395 (19.9) |
Diabetes | 34 (11.6) | 659 (5.6) |
Prediabetes | 22 (7.5) | 498 (4.1) |
Abbreviations: CCSS, Childhood Cancer Survivor Study; CHIIP, Communicating Health Information and Improving Coordination With Primary Care.
Members of the cohort who responded to the follow-up 5 survey, conducted between 2014 and 2016.
Includes those who self-reported as other or nonspecified.
Per CCSS records.